Dr. Ari Melnick

Dr. Ari M. Melnick, MD, is a world-leading medical oncologist and global authority in hematologic malignancies and cancer epigenetics. He serves as the Gebroe Family Professor of Hematology and Oncology and Chair of the Hematologic Malignancies Program at Weill Cornell Medicine. Dr. Melnick earned his medical degree from the University of Buenos Aires, completed his residency in Internal Medicine and fellowship in Hematology and Oncology at Mount Sinai Medical Center, and pursued postdoctoral research in molecular oncology at Memorial Sloan Kettering Cancer Center. He is board-certified in Internal Medicine, Hematology, and Medical Oncology and is widely recognized for his leadership in advancing epigenetic therapies for lymphoma and leukemia.

A transformative force in cancer epigenetics, Dr. Melnick’s research has focused on elucidating how transcription factors and chromatin modifiers drive the pathogenesis of B-cell malignancies. His work has led to the development of novel therapeutic strategies targeting epigenetic regulators, several of which have progressed into clinical trials and are redefining treatment paradigms in hematologic oncology. Dr. Melnick has authored over 300 peer-reviewed publications and has been a principal investigator on multiple NIH-funded research programs, with his discoveries shaping the understanding of gene regulation in lymphoma and leukemia.

In addition to his research and clinical leadership, Dr. Melnick is a dedicated educator and mentor. He has trained numerous physician-scientists and has been instrumental in fostering collaborative translational research programs. He serves on advisory boards for the Leukemia & Lymphoma Society, the Lymphoma Research Foundation, and is a member of the AACR Academy Fellows Class of 2025. Through his commitment to scientific innovation, clinical excellence, and mentorship, Dr. Ari M. Melnick continues to advance the field of hematologic oncology and improve outcomes for patients worldwide.